Release date:2016-06-06  Release:


Associate Professor of Pharmacology

School of 学院名称

Phone: 86-25-83271173


Research Summary

My research mainly focus on cardiovascular pharmacology, especially on ischemic stroke which is one of the leading cause of death all over the world. Injury induced by stroke is not restricted in the brain only. Instead, brain interacts with peripheral organs, including the immune system. Circulating leukocytes impact on brain injury after stroke, and immune cells are also involved in the long term recovery after stroke. Leukocytes in the ischemic brain include macrophages, which are composed of microglia and monocyte-derived macrophages. How macrophages derived from monocytes and microglia contribute to brain injury remain unclear. Discovering function of immune cell will facilitate their clinical translation.


2011       Ph.D., Pharmacology, China Pharmaceutical University

2004       M.S., Pharmacology, China Pharmaceutical University

2001       B.S., Medicinal business management, China Pharmaceutical University.

Academic Experience

2012-      Associate Professor of Pharmacology, China Pharmaceutical University

Awards and Honors

2016       Academic leader of young and middle-aged teacher, Qing Lan Project, Jiangsu Provincial Department of Education

2012       Outstanding young mainstay teacher, Qing Lan Project, Jiangsu Provincial Department of Education

2013       “333” high level scientist project, third level, Jiangsu province


Books: Yunman li, Weirong Fang. Cardiovascular pharmacology. Jiangsu Science Press. 2014

Papers and Articles

  1. Fang W, Sha L, Kodithuwakku ND, Wei J, Zhang R, Han D, Mao L, Li Y. Attenuated Blood-Brain Barrier Dysfunction by XQ-1H Following Ischemic Stroke in Hyperlipidemic Rats. Mol Neurobiol. 2015; 52(1): 162-75.

  2. Han D, Fang W, Zhang R, Wei J, Kodithuwakku ND, Sha L, Ma W1, Liu L, Li F, Li Y. Clematichinenoside protects blood brain barrier against ischemic stroke superimposed on systemic inflammatory challenges through up-regulating A20. Brain Behav Immun. 2016; 51: 56-69. (Co-first author)

  3. Fang W, Zhang R, Sha L, Lv P, Shang E, Han D, Wei J, Geng X, Yang Q, Li Y. Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain. J Neurochem. 2014; 128(5): 662-71.

  4. Fang W, Lv P,Geng X, Shang E, Yang Q, Sha L, Li Y. Penetration of verapamil across blood brain barrier following cerebral ischemia depending on both paracellular pathway and P-glycoprotein transportation. Neurochem Int. 2013; 62 (1): 23-30.

  5. Fang W, Deng Y, Li Y, Shang E, Fang F, Lv P, Bai L, Qi Y, Yan F, Mao L.Blood brain barrier permeability and therapeutic time window of Ginkgolide B in ischemia-reperfusion injury. Eur J Pharm Sci. 2010; 39 (1-3): 8-14.

  6. Fang W, Wei J, Han D, Chen X, He G, Wu Q, Chu S, Li Y. MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition. Thromb Res. 2014; 133 (4): 610-615

  7. Fang W,Geng X, Deng Y, Li Y, Shang E, Cen J, Lv P.Platelet activating factor induces blood brain barrier permeability alteration in vitro. J Neuroimmunol. 2011; 230 (1-2):42-7.

  8. Fang W, Li Y, Cai Y, Kang K, Yan F, Liu G, Huang W.Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo. J Pharm Pharmacol. 2007; 59 (12): 1649-55.

  9. Lv P, Fang W, Geng X, Yang Q, Li Y, Sha L. Therapeutic neuroprotective effects of ginkgolide B on cortex and basal ganglia in a rat model of transient focal ischemia. Eur J Pharm Sci. 2011; 44 (3): 235-40 (Co-first author)

  10. Deng Y, Fang W, Li Y, Cen J, Fang F, Lv P, Gong S, Mao L. Blood-brain barrier breakdown by PAF and protection by XQ-1H due to antagonism of PAF effects. Eur J Pharmacol. 2009; 616 (1-3): 43-7. (Co-first author)

  11. Yang Q, Fang W, Lv P, Geng X, Li Y, Sha L. Therapeutic Neuroprotective Effects of XQ-1H in a Rat Model of Permanent Focal Cerebral Ischemia. Pharmacology. 2012; 89 (1-2):1-6. (Co-first author)

  12. Zhang R, Fang W, Han D, Sha L, Wei J, Liu L, Li Y. Clematichinenoside attenuates myocardial infarction in ischemia/reperfusion injury both in vivo and in vitro. Planta Med. 2013; 79 (14):1289-97. (Co-first author)

  13. Wei J, Fang W, Sha L, Han D, Zhang R, Hao X, Li Y. XQ-1H Suppresses Neutrophils Infiltration and Oxidative Stress Induced by Cerebral Ischemia Injury Both In Vivo and In Vitro. Neurochem Res. 2013; 38: 2542-2549 (Co-first author)

  14. Darshika Kodithuwakku N, Pan M, Zhu YL, Zhang YY, Feng YD, Fang WR, Li YM. Anti-inflammatory and antinociceptive effects of Chinese Medicine SQ gout capsules and its modulation of pro-inflammatory cytokines focusing on gout arthritis. J Ethnopharmacol. 150 (2013) 1071–1079. (Co-corresponding author)

  15. Zhou Y, Huang J, He W, Fan W, Fang W, He G, Wu Q, Chu S, Li Y. N2 ameliorates neural injury in experimental ischemic stroke via regulation of thromboxane A2 production. Pharmacol Biochem Behav. 124 (2014) 458-465. (Co-corresponding author)

  16. Xiong Y, Ma Y, Han W, Kodithuwakku ND, Liu LF, Li FW, Fang WR, Li YM. Clematichinenoside AR induces immunosuppression involving Treg cells in Peyer׳s patches of rats with adjuvant induced arthritis. J Ethnopharmaco. 155 (2014) 1306–1314 (Co-corresponding author)

  17. Kodithuwakku ND, Feng YD, Zhang YY, Pan M, Fang WR, Li YM. The molecular insight into the antihyperuricemic and renoprotective effect of Shuang Qi gout capsule in mice. J Ethnopharmacol. 163 (2015): 278-89 (Co-corresponding author)

  18. Huang J, Kodithuwakku ND, He W, Zhou Y, Fan W, Fang W, He G, Wu Q, Chu S, Li Y. The neuroprotective effect of a novel agent N2 on rat cerebral ischemia associated with the activation of PI3K/Akt signaling pathway. Neuropharmacology. 95 (2015): 12-21. (Co-corresponding author)

  19. Yang L, Chen X, Wang S, Fei Y, Wang D, Li Y, He G, Wu Q, Chu S, Fang W. N2 extenuates experimental ischemic stroke through platelet aggregation inhibition. Thromb Res. 2015; 136 (6): 1310-7 (Co-corresponding author)